INSIGHTS ON EMERGING CAR T THERAPIES

Patients with high tumor burden are predisposed to less favorable outcomes after chimeric antigen receptor T-cell (CAR T) therapy, but researchers say radiomic cytoreduction achieved during...

Researchers at Stanford University have conducted a phase 1 clinical trial (#NCT03233854) evaluating the combination of a bispecific chimeric antigen receptor (CAR) T-cell therapy targeting CD19...

The potential for secondary myelodyspastic syndromes (MDS) following chimeric antigen receptor (CAR) T-cell therapy in children with acute lymphoblastic leukemia (ALL) is a real concern,...

The following infographics are based on New Developments in CAR T Treatments Webinar Series, which aired on Tuesday, September 10, at 12 p.m. CDT and featured two presentations from Drs....

The "New Developments in CAR T Treatments" webinar series, held on September 10, 2024, brought together leading experts in the field of cancer immunotherapy to discuss the latest...

Researchers say interleukin 4 (IL-4) is implicated in chimeric antigen receptor (CAR) T-cell exhaustion — a primary factor blocking durable response to CAR immunotherapy — and thus may...